Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

30.0%

3 terminated/withdrawn out of 10 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

40%

4 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3

4(66.7%)

Phase 2

1(16.7%)

N/A

1(16.7%)

6Total

Phase 3(4)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT03896685Phase 3Completed

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)

Role: lead

NCT02754765Phase 3Completed

Evaluating Newly Approved Drugs for Multidrug-resistant TB

Role: lead

NCT04853186Recruiting

Impact Study of Cholera Vaccination in Endemic Areas - Clinical Surveillance

Role: collaborator

NCT03259269Completed

Expand New Drugs for TB [endTB]

Role: collaborator

NCT04152486Phase 3Unknown

Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC

Role: collaborator

NCT04250168Terminated

Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response

Role: collaborator

NCT02994212Not ApplicableCompleted

Reduced Visit Frequency in the Treatment of Uncomplicated Severe Acute Malnutrition: Evaluation of Operational Feasibility and Safety

Role: collaborator

NCT03370003Completed

Non-routine Use of Antibiotics (Amoxi-light)

Role: collaborator

NCT00489658Phase 2Terminated

Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda

Role: collaborator

NCT00330148Phase 3Terminated

Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis

Role: collaborator

All 10 trials loaded